Acticor Biotech

Acticor Biotech EBIT per Share

Delisted

The EBIT per Share of Acticor Biotech (ALACT.PA) as of Nov 7, 2026 is -1.46 EUR. In the previous year, EBIT per Share was -1.43 EUR — a change of 1.51% (lower).

EBIT per Share

-1.46EUR

YoY

1.51%

Last updated:

EBIT per Share of Acticor Biotech is 2023 -1.46 EUR. EBIT per Share of Acticor Biotech was 2022 -1.43 EUR. It decreases by 1.51% lower compared to the previous year.

The Acticor Biotech EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2019
-0.49 EUR
Jan 1, 2020
-0.72 EUR
Jan 1, 2021
-1.53 EUR
Jan 1, 2022
-1.43 EUR
Jan 1, 2023
-1.46 EUR
Jan 1, 2024 (e)
3.67 EUR
Jan 1, 2025 (e)
-0.17 EUR
Jan 1, 2026 (e)
1.45 EUR
The Acticor Biotech EBIT per Share history
YEAREBIT per ShareYoY
est1.45EUR-950.00%
est-0.17EUR-104.65%
est3.67EUR-352.15%
-1.46EUR+1.51%
-1.43EUR-6.17%
-1.53EUR+112.71%
-0.72EUR+46.68%
-0.49EUR+22.58%
-0.40EUR-28.76%
-0.56EUR+1,778.97%
-0.03EUR-93.68%
-0.47EUR-170.69%
0.67EUR-16.88%
0.80EUR-13.03%
0.92EUR+26.23%
0.73EUR+274.88%
0.20EUR+423.08%
0.04EUR+18.18%
0.03EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Acticor Biotech Stock analysis

What does Acticor Biotech do? Acticor Biotech SA develops antithrombotic agents for acute thrombotic diseases, focusing on acute ischemic strokes and pulmonary embolisms. The company has one product, Glenzocimab, in Phase II clinical development, alongside pipeline products ACTIMIS, GARDEN, ACTISAVE, and GREEN. It collaborates with partnering companies Ouest Valorisation, Genopole, Medicine, and Inserm for research and development. Acticor Biotech SAS is a clinical stage biopharmaceutical company spun off from INSERM, with 24 full-time employees. The firm generates revenue through its research and development activities, leveraging its partnership with INSERM and other institutions. Glenzocimab, its lead product, is in Phase II trials, indicating potential future licensing agreements or sales. The company's pipeline products ACTIMIS, GARDEN, ACTISAVE, and GREEN represent additional revenue streams once they progress through clinical development. Acticor Biotech targets the biopharmaceutical sector, specifically focusing on thrombotic disease treatments. Its primary customers are pharmaceutical companies seeking to license or co-develop novel antithrombotic therapies. The company's partnerships with Ouest Valorisation, Genopole, Medicine, and Inserm facilitate its R&D efforts and potential commercialization pathways. Acticor Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acticor Biotech stock

EBIT per Share of Acticor Biotech is -1.46 EUR in 2023.

EBIT per Share of Acticor Biotech changed from -1.43 EUR to -1.46 EUR, representing a 1.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Acticor Biotech since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Acticor Biotech

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Acticor Biotech